Organization
University of Colorado Anschutz Medical Campus
14 abstracts
3 posters
Abstract
A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.Org: University of Colorado School of Medicine, University of Colorado Denver, Agenus, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center,
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
Healthcare spending after a cancer diagnosis among working-aged adults.Org: University of Minnesota, University of Colorado Cancer Center, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, American Cancer Society,
Abstract
The future is now: Implementation of standard of care, preemptive pharmacogenomic testing in patients with gastrointestinal cancers.Org: UCHealth, University of Colorado Anschutz Medical Campus, University of Colorado School of Medicine, University of Colorado Cancer Center, Division of Medical Oncology, National Cancer Center Singapore,
Abstract
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).Org: University of Colorado Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Colorado Anschutz Medical Campus, Inova Schar Cancer Institute,
Abstract
Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Colorado Anschutz Medical Campus, Division of Gynecologic Oncology, University of Pennsylvania, Department of Obstetrics & Gynecology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Abstract
Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing.Org: University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, University of Colorado School of Medicine, Veterans Affairs Medical Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Prediction of cancer treatment response from histopathology images through imputed transcriptomics.Org: Pangea Biomed, University of Pittsburgh, Pittsburgh, PA, Sheba Medical Center at Tel-Hashomer, University of Colorado School of Medicine, Department of Oncology and Cancer Research UK Cambridge Institute,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Using cell-free DNA to predict response to immunotherapy in non-small cell lung cancer pre- and post-treatment.Org: University of Colorado Denver Anschutz Medical Center, University of Colorado Cancer Center, University of Colorado Denver | Anschutz Medical Campus, Division of Medical Oncology, University of Colorado, Drammen Hospital. Dept. of Oncology.,
Abstract
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.Org: Dana-Farber Cancer Institute, University of Colorado Anschutz Medical Campus, Harvard Medical School, University of Colorado Boulder, University of Pennsylvania,